FAQFAQ   SearchSearch   MemberlistMemberlist   UsergroupsUsergroups 
 ProfileProfile   PreferencesPreferences   Log in to check your private messagesLog in to check your private messages   Log inLog in 
Forum index » Medicine forums » laboratory
Nanobac, Diagnostics, Kidney Diseases & Prostate Disease
Post new topic   Reply to topic Page 1 of 1 [1 Post] View previous topic :: View next topic
Author Message
NanoBiotech Reviews
medicine forum beginner


Joined: 09 Jun 2005
Posts: 22

PostPosted: Fri Mar 31, 2006 4:40 pm    Post subject: Nanobac, Diagnostics, Kidney Diseases & Prostate Disease Reply with quote

March 31, 2006 09:17 AM US Eastern Timezone
Nanobac Pharmaceuticals Announces Sharpened Focus
TAMPA, Fla.--(BUSINESS WIRE)--March 31, 2006--Nanobac Pharmaceuticals,
Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") today announced a
sharpened focus on developing safe and effective drug therapies for
diseases where calcification, or "calcium deposits", is a dominant
feature.
Calcification is a significant feature in most diseases that are
leading causes of death, including heart disease. Calcification is
shown in numerous studies to block circulation, cause inflammation and
cell disruption, and is a possible sign of cancers. More than 20,000
journal papers reference it, but until now it has been hard to treat.
The sharpened focus on drug therapy is based on findings by Nanobac
scientists that certain drugs, when combined, are effective at halting
the calcification process.
Some of these drug combinations have not been tested in animals or
humans. However, the Company has an advantage in that each of these
drugs on its own has an FDA-approved record of being safe, therefore
regulatory hurdles are significantly lower in every national
jurisdiction.
In announcing this sharpened focus, company Co-Chairman Dr. Benedict
Maniscalco explained that this denotes a major shift so that the
Company can develop what it considers to be a group of major new
findings.
The Company will focus on the following priorities over the next 12-18
months:
-- Therapy. The Company is entering into agreements to test its
proprietary drug combinations to treat stone-forming diseases, with a
preliminary focus on prostatitis, which affects millions of men and
currently is largely untreatable. The Company will also conduct tests
with other stone forming diseases such as gallstones and kidney stones.

-- Infection. The gold standard for proving that something is
infectious is Koch's postulates, and the company will validate earlier
findings on Koch's postulates with calcifying nanoparticles in
laboratory animals, including testing whether the infection can be
prevented or treated with a proprietary drug combination.
-- Characterization. The Company has preliminary photographic and
biochemical evidence that calcifying nanoparticles self-replicate in
non-precipitating conditions, suggesting further that they have the
ability to be infectious. The Company has designed an experiment with
NASA to demonstrate this via time-lapse photography, using new
microscopic technology developed in 2005.
-- Thrombosis is the cause of death in most hemodialysis patients. The
Company intends to validate its findings that calcifying nanoparticles
discovered in human blood provoke thrombosis and might be preventable.
-- Diagnostics. The Company believes that its proprietary Elisa
antibody test uniquely recognizes calcifying nanoparticles known as
nanobacteria, and plans to validate this immediately.
"The Company will continue optimizing its proprietary diagnostics, with
a clear focus on developing effective therapies in cooperation with
well-established partners including NASA, Mayo Clinic, Cleveland
Clinic, and numerous other institutions. Once these experiments are
completed, we will have a compelling and well-rounded scientific basis
for the Company to move forward," Dr. Maniscalco concluded.
About Nanobac Pharmaceuticals
Nanobac Pharmaceuticals, Inc. is a broad-based life science company
dedicated to the discovery and developments of products and services to
improve people's health through the detection and treatment of
Calcifying Nano-Particles, otherwise known as "nanobacteria". The
Company's pioneering research is establishing the pathogenic role of
nanobacteria in soft tissue calcification, particularly in coronary
artery heart disease, prostatitis and vascular disease.
Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and
reagents for the detection of Calcifying Nano-Particles. IVD products
include the NANOCAPTURE(TM) and NANO-SERO(TM) ELISA assays and the
Nano-Vision(TM) line of antibodies and reagents. Nanobac's
BioAnalytical Services works with biopharmaceutical partners to develop
and apply methods for avoiding, detecting, and inactivating or
eliminating CNPs from raw materials. Nanobac's Drug Discovery and
Development efforts are focused on developing new and existing
compounds that effectively inhibit, destroy or neutralize CNPs.
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For
more information, please visit our website at: http://www.nanobac.com.
Investors are cautioned that certain statements contained in this
document as well as some statements in periodic press releases and some
oral statements of Nanobac Pharmaceuticals, Inc. officials are
"Forward-Looking Statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking
statements include statements which are predictive in nature, which
depend upon or refer to future events or conditions, which include
words such as "believes," "anticipates," "intends," "plans," "expects,"
and similar expressions. In addition, any statements concerning future
financial performance (including future revenues, earnings or growth
rates), ongoing business strategies or prospects, and possible future
Nanobac Pharmaceuticals, Inc. actions, which may be provided by
management, are also forward-looking statements as defined by the Act.
Forward-Looking statements involve known and unknown risks,
uncertainties, and other factors which may cause the actual results,
performance or achievements of the Company to materially differ from
any future results, performance or achievements expressed or implied by
such forward-looking statements and to vary significantly from
reporting period to reporting period. Although management believes that
the assumptions will, in fact, prove to be correct or that actual
future results will not be different from the expectations expressed in
this report. These statements are not guarantees of future performance
and Nanobac Pharmaceuticals, Inc. has no specific intention to update
these statements.
Contacts
Nanobac Pharmaceuticals, Inc., Tampa
Karen Taylor, 813-264-2241
Back to top
Google

Back to top
Display posts from previous:   
Post new topic   Reply to topic Page 1 of 1 [1 Post] View previous topic :: View next topic
The time now is Wed Aug 22, 2018 5:03 am | All times are GMT
Forum index » Medicine forums » laboratory
Jump to:  

Similar Topics
Topic Author Forum Replies Last Post
No new posts Battling Lyme disease mark_denton2006@yahoo.com lyme 0 Tue Jul 18, 2006 7:46 pm
No new posts Schumer addresses Lyme disease mark_denton2006@yahoo.com lyme 0 Tue Jul 18, 2006 7:43 pm
No new posts Kelly met with CDC on Lyme disease mark_denton2006@yahoo.com lyme 0 Tue Jul 18, 2006 7:42 pm
No new posts Rep. Smith pushes for Lyme disease bill as NJ cases skyro... mark_denton2006@yahoo.com lyme 0 Tue Jul 18, 2006 7:39 pm
No new posts Gum disease can lead to more than unhealthy mouth Roman Bystrianyk dentistry 1 Tue Jul 18, 2006 4:27 pm

Copyright © 2004-2005 DeniX Solutions SRL
Other DeniX Solutions sites: email marketing campaigns , electronics forum, Science forum, Unix/Linux blog, Unix/Linux documentation, Unix/Linux forums


Powered by phpBB © 2001, 2005 phpBB Group
[ Time: 0.0155s ][ Queries: 16 (0.0033s) ][ GZIP on - Debug on ]